Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer

NovoCure Ltd

CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.
mOS 16.2 vs 14.2 months (HR 0.82, p=0.039) in ITT; 18.3 vs 15.1 months in mITT.
Time to pain progression extended 6.1 months (15.2 vs 9.1 months, HR 0.74, p=0.027).
Optune Pax already FDA-approved Feb 2026; launch in Germany planned in coming weeks.
Device well-tolerated; most AEs mild-moderate skin events; no new safety signals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.